Keywords
Histamine
Bradykinin
Idiopathic angioedema
Urticaria
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase
Abstract
Angioedema is defined as edema of the skin or mucosa, including the respiratory and the gastrointestinal mucosa, which is self-limiting, and in most cases is completely resolved in less than 72 hours. It occurs due to increased permeability of the mucosal and submucosal capillaries and postcapillary venules, with resulting plasma extravasation. There are different types of angioedema: histaminergic (which may be mediated by immunoglobulin E), hereditary, from acquired C1 inhibitor deficiency, from angiotensin converting enzyme inhibitor, bradykinin-mediated, and non-histaminergic idiopathic angioedema. Treatment depends on the cause of angioedema, age, and the frequency and severity of manifestations. The main measures are avoiding external triggers or causes, giving antihistamines, steroids, or adrenaline for histaminergic angioedema; replacing the deficient protein or blocking the action of bradykinin in C1 inhibitor deficiency and angioedema from angiotensin converting enzyme inhibitor.References
Kaplan AP. Angioedema. World Allergy Organ J. 2008;1(6):103-113. doi:10.1097/ WOX.0b013e31817aecbe
Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015 May;277(5):585-593. doi: 10.1111/joim.12304
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA2LEN/ EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update. Allergy Eur J Allergy Clin Immunol. 2014;69(7):868-887. doi:10.1111/all.12313
Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777-787. doi:10.1111/j.1365-2222.2009.03256.x.
Wu MA, Perego F, Zanichelli A, Cicardi M. Angioedema phenotypes: Disease expression and classification. Clin Rev Allergy Immunol. 2016;51(2):1-8. doi:10.1007/s12016-016-8541-z
Mahendran K, Padmini G, Murugesan R, Srikumar A. Acute allergic angioedema of upper lip. J Conserv Dent. 2016;19(3):285. doi:10.4103/0972-0707.181949
Temiño VM, Peebles RS. The spectrum and treatment of angioedema. Am J Med. 2008;121(4):282-286. doi:10.1016/j.amjmed.2007.09.024
Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. Atlanta, GA, USA: Elsevier; 2014.
Jares EJ, Sánchez-Borges M, Cardona-Villa R, Ensina LF, Arias-Cruz A, Gómez M, et al. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy, Asthma Immunol. 2014;113(3):282-289. doi:10.1016/j.anai.2014.06.019
Torres MJ, Barrionuevo E, Kowalski M, Blanca M. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Immunol Allergy Clin North Am. 2014;34:507-524. doi:10.1016/j.iac.2014.04.001
Cornejo-García JA, Blanca-López N, Dona I, Andreu I, Agúndez JA, Carballo M, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab. 2009;10(9):971-980. doi:10.1016/j. iac.2014.04.001
Adkinson NF, Bochner BS, Burks W, Busse, William W, Holgate ST, et al. Middleton’s allergy principles and practice. Octava edición. Atlanta, GA, USA: Elsevier; 2014.
Abajian M, Mlynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep. 2012;12(4):281-287. doi:10.1007/s11882-012-0269-0
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, et al. The definition, diagnostic testing and management of chronic inducible urticarias. Update and revision of the EAACI/ GA2LEN/EDF/UNEV 201 consensus recommendations 2016 update and revision. Allergy. 2016;71:780- 702. doi:10.1111/all.12884
Parra V, Darío-Aguirre H, Daza RA, Mora SA, Peñaranda E. Lupus eritematoso sistémico versus urticaria vasculítica hipocomplementémica: un dilema diagnóstico en la práctica clínica. Rev Colomb Reumatol. 2015;22(3):168-173.
Chang S, Carr W. Urticarial vasculitis. Allergy Asthma Proc. 2007;28(1):97-100. doi:10.2500/aap.2007.28.2972
Pulido-Pérez A, Avilés-Izquierdo JA, Suárez-Fernández R. Vasculitis cutáneas. Actas Dermosifiliogr. 2012;103(3):179-191. doi:10.1016/j.ad.2011.06.00.
Maitra A. Endocrine system. En: Kumar V, Abbas AK, Aster JC, editores. Robbins basic pathology. Novena edición. Philadelphia: Elsevier Saunders; 2013. p. 715-764.
Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des. 2004;10(6):589-601. doi:10.2174/1381612043453108
Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(5):413-421. doi:10.1016/S0002-9343(98)00091-6
Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res. 2011;3(1):3. doi:10.4168/aair.2011.3.1.3.
Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136(2):245-251. doi:10.1016/j.jaci.2015.06.021.
Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-López N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy Eur J Allergy Clin Immunol. 2013;68(10):1219-1232. doi:10.1111/all.12260.
Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol. 1998;101(5):581-586. doi:10.1016/S0091- 6749(98)70163-0
Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000;15(5):863-869.
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62(10):1111-1118. doi:10.1111/j.1398-9995.2007.01409.x
Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172-174. doi:10.1016/S1081-1206(10)60692-8
Asero R. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy. 2005;35(6):713-716. doi:10.1111/j.1365-2222.2005.2228.x
Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209(2):209-216. doi:10.1016/j.tox.2004.12.024.
Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45(6):321-328.
Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009;15(2):69-78. doi:10.1016/j.molmed.2008.12.001
Zeerleder S, Levi M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann Med. 2016;3890:1-12. doi:10.3109/07853890.2016.1162909
Craig TJ, Pürsün EA, Bork K, Bowen T, Boysen H, Farkas H, et al. WAO Guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5(12):182-199. doi:10.1097/ WOX.0b013e318279affa
Riedl MA. Hereditary angioedema with normal C1-INH (HAE Type III). J Allergy Clin Immunol Pract. 2013;1(5):427-432. doi:10.1016/j.jaip.2013.06.004.
Drouet C, Désormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, et al. Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121(2):429-433. doi:10.1016/j.jaci.2007.10.048
Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114(1):3-9.
Walford HH, Zuraw BL. Current update on cellular and molecular mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol. 2014;112(5):413-418. doi:10.1016/j.anai.2013.12.02
Atkinson JP, Cicardi M, Zuraw BL, Saini S FA. Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis. UpToDate. 2014:1-11.
Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: Clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124(1):129-134. doi:10.1016/j.jaci.2009.03.038
Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616. doi:10.1111/all.12380
Scalese MJ, Reinaker TS. Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors. Am J Heal Pharm. 2016;73(12):873-879. doi:10.2146/ajhp150482
Wilkerson RG. Angioedema in the emergency department: an evidence-based review. Emerg Med Pract. 2012;14(11):1-21.
Church MK, Maurer M, Simons FER, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: A GA(2)LEN position paper. Allergy Eur J Allergy Clin Immunol. 2010;65(4):459-466. doi:10.1111/j.1398-9995.2009.02325.x
Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676-682. doi:10.1016/j.jaci.2009.11.047
Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy Eur J Allergy Clin Immunol. 2013;68(7):921-928.
Tubert-Brohman I, Sherman W, Repasky M, Beuming T. Improved docking of polypeptides with glide. J Chem Inf Model. 2013;53(7):1689-1699. doi: 10.1021/ci400128m
Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007;99(2):190-193. doi:10.1016/S1081-1206(10)60644-8
Büyüköztürk S, Gelincik A, Demirtürk M, Kocaturk E, Çolakoǧlu B, Dal M. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey. J Dermatol. 2012;39(5):439-442. doi:10.1111/j.1346-8138.2011.01473.x
Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154(2):177-180.
Nurnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol. 1995;75(1):54-56.
Wiles JC, Hansen RC, Lynch PJ. Urticarial vasculitis treated with colchicine. Arch Dermatol. 1985;121(6):802-805. doi:10.1001/archderm.1985.01660060116035.
Lopez LI, Davis KC, Kohler PF, Schocket AL. The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol. 1984;73(5 Pt 1):600-603.
Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, Gómez-Traseira C, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011;21(5):333-347.
Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, et al. Hereditary angiodema: A current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy, Asthma Immunol. 2008;100(1):S30-S40. doi:10.1016/S1081-1206(10)60584-4
Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, et al. Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004;114(3):629-637. doi:10.1016/j.jaci.2004.06.043
Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol. 2005;139(3):379-394. doi:10.1111/j.1365-2249.2005.02726.x
Charignon D, Ghannam A, Defendi F, Ponard D, Monnier N, López Trascasa M, et al. Hereditary angioedema with F12 mutation: Factors modifying the clinical phenotype. Allergy. 2014;69(12):1659- 1665. doi: 10.1111/all.12515
Charignon D, Späth P, Martin L, Drouet C. Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin Pharmacother. 2012;13(15):2233-2247. doi:10.1517/146 56566.2012.723692
Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532-541. doi:10.1056/ NEJMoa0906393
Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529-537. doi:10.1016/j. anai.2011.08.015
Czaller I, Visy B, Csuka D, Füst G, Tóth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: A long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):44-49. doi:10.1016/j.ejogrb.2010.05.008
Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808. doi:10.1016/j.jaci.2009.07.017
Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy Eur J Allergy Clin Immunol. 2011;66(12):1604-1611. doi:10.1111/j.1398-9995.2011.02702.x
Xu YY, Buyantseva LV, Agarwal NS, Olivieri K, Zhi YX, Craig TJ. Update on treatment of hereditary angioedema. Clin Exp Allergy. 2013;43(4):395-405. doi:10.1111/cea.12080
Riedl M, Campion M, Horn PT, Pullman WE. Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy, Asthma Immunol. 2010;105(6):430-436.e2. doi:10.1016/j. anai.2010.09.005
Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol. 2011;128(1):153-159. doi:10.1016/j.jaci.2011.03.006
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2016 Revista Alergia México